• Home
  • Study Details
COM_RESEARCHSTUDIES_DETAIL_AVAL_STATUS_4

Dara-RVd Induction for newly diagnosed multiple myeloma with autologous stem cell transplantation

In this study, we want to see what happens when one of the drugs in a 4-drug combination called Dara-RVd is given once a week instead of twice a week. We will look at how this timing change affects the outcome of multiple myeloma with autologous stem cell transplantation. This is a hybrid decentralized study where some if not all assessments may be performed close to your home.

Age & Gender

  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive

Contact the Team

Location

COM_RESEARCHSTUDIES_DETAIL_HEADER_BASIC_CONTACT_4

United States (Nationwide)

Additional Study Information

Principal Investigator

Samuel Rubinstein
Lineberger Comprehensive Cancer Center

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Multiple Myeloma)

IRB Number

24-1966

ClinicalTrials.gov

NCT06338147

Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research